Document is current

Article History

Received: 14 December 2022

Accepted: 9 March 2023

First Online: 21 March 2023

Change Date: 30 March 2023

Change Type: Update

Change Details: An error was found in the article title. The article has been updated to rectify the errors.

Declarations

:

: The study was performed according to Helsinki Declaration and approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REK 2013/2371) and local ethics committees in Denmark and Sweden. Patients´ data were collected through the European Cerebrovascular Research Infrastructure (ECRI) and stored in the Services for Sensitive Data (TSD) at the University of Oslo. Written informed consent was obtained from all participants. Study is registered at ClinicalTrials.gov, Identifier: NCT02937077, (18/10/2016).

: Written informed consent was obtained from all participants.

: DA has received honoraria and consultation fees from Actelion, Amgen, AstraZeneca, BMS/Pfizer, Bayer, Boehringer-Ingelheim, MSD, Novartis, Roche Diagnostics, Sanofi, Takeda, and Vifor Pharma; and research funding (to the institution) from BMS/Pfizer, Bayer, Roche Diagnostics and Medtronic. AHA has received travel support and honoraria for advice or lecturing from Allergan, Bayer, BMS, Boehringer Ingelheim, Novartis, Roche, Sanofi-Genzyme and Teva; research grant from Boehringer Ingelheim and partial financial support from Medtronic and BMS for operating costs in ongoing clinical studies. ATL and BRT have received travel funding from Medtronic.